We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Eton Pharmaceuticals Inc (ETON) USD0.001

Sell:$2.79 Buy:$3.15 Change: $0.05 (1.59%)
NASDAQ:0.52%
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Sell:$2.79
Buy:$3.15
Change: $0.05 (1.59%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Sell:$2.79
Buy:$3.15
Change: $0.05 (1.59%)
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Contact details

Address:
21925 W Field Pkwy Ste 235
DEER PARK
60010-7278
United States
Telephone:
+1 (847) 7877361
Website:
https://etonpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ETON
ISIN:
US29772L1089
Market cap:
$81.94 million
Shares in issue:
25.69 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Sean Brynjelsen
    President, Chief Executive Officer, Director
  • James Gruber
    Chief Financial Officer, Treasurer, Company Secretary
  • David Krempa
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.